Robbins Umeda LLP Announces an Investigation of the Acquisition of SenoRx, Inc. by C.R. Bard, Inc.

Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the Board of Directors of SenoRx, Inc. ("SenoRx") (NASDAQ: SENO) in connection with their actions in causing SenoRx to enter into a definitive merger agreement with C.R. Bard, Inc. (NYSE: BCR). If the transaction is completed, SenoRx shareholders will receive $11.00 in cash for each share of SenoRx they own. The companies expect the transaction to close in the third quarter of 2010.

Robbins Umeda LLP's investigation concerns whether SenoRx's Board of Directors undertook a fair process to obtain fair consideration for all shareholders of SenoRx.

If you are a shareholder of SenoRx and would like more information about your rights as a shareholder, please contact attorney Lauren Levi at 800-350-6003 or by e-mail at llevi@robbinsumeda.com.

Robbins Umeda LLP is a California-based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions. For more information about the firm, please go to http://www.robbinsumeda.com.

Senorx (MM) (NASDAQ:SENO)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024